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ABSTRACT 
Background: Of the enzymes involved in the metabolism of azathioprine, 
thiopurine methyltransferase (TPMT) is the one characterized bygenetic poly- 
morphisms and ethnic variations. There have been several studies of the ethnic 
variations in phenotype and genotype of TPMT, although few have assessed the 
possible correlation between TPMT activity and 6-thioguanine ucleotide (6-TGN) 
concentrations. 
Objective: The aim of this study was to examine the relationship between 
TPMT activity and the steady-state concentration (Cs~) of 6-TGN, the primary 
active metabolite of azathioprine, in red blood cells (Pd3Cs) in Han Chinese 
patients treated with azathioprine. 
Methods: Han Chinese patients aged 18 to 60 years with immunosuppres- 
sion and normal hepatic and renal function who had been receiving a stable 
dose (25-100 mg/d) of oral azathioprine as a part of their regular anti- 
immunosuppression regimen for at least 10 days were recruited for this 1-year, 
single-center, prospective study. Azathioprine was administered PO QD in the 
morning, in combination with a stable regimen of other immunosuppressive 
drugs, for 1 year. At 1 year, blood samples were drawn just before the ingestion 
of azathioprine. TPMT activity and 6-TGN Css in RBCs were determined in our 
laboratory using high-performance liquid chromatography. Adverse drug 
events were monitored by a patient questionnaire and laboratory testing. Out 
of the initial cohort, several patients were concurrently enrolled in a subanaly- 
sis in which the effect of TPMT polymorphism on the pharmacokinetic prop- 
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erties of 6-mercaptopurine, the intermediate metabolite of azathioprine, was 
examined. 
Results: Nineteen patients (14 women, 5 men; mean [SD] age, 41 [9.6] years 
[range, 22-59 years]; mean [SD] weight, 62 [12] kg) were included in the study; 
7 were included in the subanalysis. A significant negative correlation was found 
between TPMT activity and 6-TGN Css in RBCs (r = -0.712; P = 0.001); when the 
outlier data were removed, no significant correlation was found. Mean (SD) 
TPMT activity was 12.95 (3.07) nmol/h • mL -1 RBCs and the interindividual CV 
was 23.68%. Mean (SD) 6-TGN Css was 42.95 (41.98) ng/8 x 108 RBCs and the 
interindividual CV was 97.74% (N = 19), while the intraindividual CV of 6-TGNs 
within 8 hours after azathioprine ingestion was between 4.23% and 7.37% (n = 
7). No significant correlation was found between 6-TGN Css in RBCs and the 
dose of azathioprine used. One patient's treatment was discontinued because 
her white blood cell count decreased to <4 x 109 cells/L, indicating myelotoxi- 
city; the tl/2 of 6-TGNs in this patient was 5.85 days. Treatment was well toler- 
ated by all other patients. 
Conclusion: In this small study, a significant negative correlation was found 
between TPMT activity and 6-TGN concentration in the RBCs of these Hart 
Chinese patients. However, the correlation was not significant when data from 
1 patient with low TPMT activity were excluded. (Curr Ther Res Clin Exp. 2006; 
67:270-282) Copyright © 2006 Excerpta Medica, Inc. 
Key words: thiopurine methyltransferase, azathioprine, 6-thioguanine nucleo- 
tides, genetic polymorphism. 
INTRODUCTION 
Azathioprine has been used extensively to treat immunosuppression i  
autoimmune diseases and organ transplantation for nearly 40 years. 1 Since 
2000, a better  understanding of azathioprine metabol ism has been 
gained. 1,2 Azathioprine is cleaved to 6-mercaptopurine (6-MP) in vivo by 
glutathione. The 6-MP is then metabolized via 3 competit ive routes: (1) by 
thiopurine methyltransferase (TPMT), resulting in the formation of 6- 
methyl-mercaptopurine (6-MeMP); (2) by xanthine oxidase (XO), resulting 
in the formation of the inactive metabolite 6-thiouric acid, which is 
excreted by the kidneys; and (3) by hypoxanthine-guanine phosphor ibosyl  
transferase (HGPRT), resulting in the formation of 6-thioguanine nu- 
cleotides (6-TGNs), which are the primary active metabolites of azathio- 
prine (Figure 1). 
Of the enzymes involved in the metabolism of azathioprine, TPMT is the one 
characterized by genetic polymorphisms and ethnic variations. For example, in 
1 study, aTPMT activity displayed a trimodal distribution in a white population: 
-89% inherited 2 wild-type alleles with normal (or high) activity; 11% were het- 
erozygous for mutant/wild-type alleles with intermediate activity; and -0.3% 
inherited 2 mutant alleles with negligible TPMT activity. In another study in a 
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Figure 1. The metabolic pathway of azathioprine. 6-MeMP = 6-methyl-mercaptopurine; 
TPMT = thiopurine methyltransferase; 6-MP = 6-mercaptopurine, XO = 
xanthine oxidase; 6-TU = 6-thiouric acid; HGPRT = hypoxanthine-guanine 
phosphoribosyl transferase; 6-TGNs = 6-thioguanine nucleotides. TPMT, 
XO, and HGPRT represent the 3 competitive routes by which 6-MP is 
metabolized. 
white population, 4 the frequency of individuals with a variant TPMT allele was 
10.1%, with TPMT*3A being the most common mutant allele. However, in a 
study in 192 Han Chinese patients, 5 unimodal distribution was found in TPMT 
activity, with the mean (SD) activity being 12.12 (3.27) U/mL red blood cells 
(RBCs). The frequency of mutant alleles was 4.7% (9/192); the most common 
mutant allele was TPMT*3C. 5 
Several studies have assessed the ethnic variations in the phenotype and 
genotype of TPMT, 6-9 although few studies have assessed both TPMT activ- 
ity and 6-TGN concentrations. 3 The correlation between TPMT activity and 
the 6-TGN concentration i  RBCs remains controversial. 1°-14 A search of the 
literature did not find any such studies in the Han Chinese population (Chinese 
Biomedical Literature Database search [in Chinese]; key terms: azathio- 
prine, thiopurine methyltransferase, 6-thioguanine, and polymorphism; years: 
1978-2005). Furthermore, in patients with high TPMT activity, 6-MP is read- 
ily metabolized into 6-MeMP by TPMT, decreasing the production of 6-TGNs. 
For these reasons, we examined the relationship between TPMT activity 
and steady-state 6-TGN concentration (Css) in the RBCs of Han Chinese 
patients. 
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PATIENTS AND METHODS 
Study Design 
This 1-year, single-center, prospective study was conducted at Peking Union 
Medical College Hospital (Beijing, China). Han Chinese patients aged 18 to 
60 years with immunosuppression and normal hepatic and renal function who had 
been receiving azathioprine as a part of their regular anti-immunosuppression 
regimen at a stable dose (25-100 mg/d) for at least 10 days were recruited 
for this study. According to a previous study, 15 6-TGNs reach Css 7 to 10 days 
after the initiation of azathioprine therapy. Patients receiving concomitant medi- 
cations that might affect the metabolism of azathioprine, such as XO inhibitors 
(eg, sulfasalazine or allopurinol) or liver microsomal enzyme inducers or in- 
hibitors, 3were excluded. Patients who had received a blood transfusion within 
4 months before the study were also excluded. Written informed consent was 
obtained from each patient before enrollment, and the study was approved by 
the institutional review board of our institution. 
Azathioprine was administered PO QD in the morning, in combination with a 
stable regimen of other immunosuppressive drugs, for 1 year. At 1 year, a blood 
sample was collected from each patient in 5-mL heparinized tubes just before 
the ingestion of azathioprine. For a subanalysis in which the effect of TPMT 
polymorphism on the pharmacokinetic properties of 6-MP, the intermediate 
metabolite of azathioprine, was examined, blood samples were also drawn at 
0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after azathioprine 
administration i some patients. 
Tolerability was assessed by adverse vents elicited using a patient question- 
naire and routine laboratory tests (blood [including liver and kidney function 
studies] and urine tests) administered once a week for the first month and once 
a month for the remainder of the study. Treatment with azathioprine was to be 
discontinued in any patient whose white blood cell (WBC) count decreased to 
<4 × 109 cells/L, indicating myelotoxicity, and blood testing was to be done week- 
ly thereafter until the WBC count returned to normal (4.5-11.0 × 109 cells/L). 
The tl/2 of 6-TGN in RBCs was to be determined in the patients who discontin- 
ued azathioprine treatment. 
Blood Sample Preparation 
Blood samples were processed according to the method used by 
Weinshilboum et al.16 Briefly, samples were centrifuged at 300g for 10 minutes 
at 4°C, and the plasma was discarded. The RBCs were washed twice in isotonic 
saline, and then 2 mL of isotonic saline was added to the pellets. After the cells 
were resuspended, hematocrit and RBC count were measured using an auto- 
mated cell counter (Celltac MEK-6108k, Nihon-Kohdon, Tokyo, Japan). Then, 
0.5 mL of the resuspended RBCs was added to 2 mL of ice-cold water, resulting 
in the lysis of the RBCs. The RBC lysates were centrifuged (RC5C, Sorvall 
Instruments, DuPont, Wilmington, Delaware) at 13,000g for 15 minutes at 4°C, 
and the supernatant was used for the TPMT assay. The remaining resuspended 
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RBCs were used for the 6-TGN assay. Samples were frozen at approximately 
-80°C until analyzed. 
Thiopurine Methyltransferase Activity Assay 
TPMT activity in RBCs was determined using a slightly modified high- 
performance liquid chromatography (HPLC) assay, as described previously. 16,17 
Metronidazole was used as the internal standard in this assay. 18The retention 
time of metronidazole is similar to that of azathioprine; no interference peaks 
were found in the retention time of metronidazole. The stability of metronidazole 
was verified using HPLC. Based on the TPMT-cataiyzed conversion of 6-MP to 
6-MeMP using S-adenosyl-L-methionine (SAM) as the methyl donor, 100 pL of the 
RBC lysate was incubated with 100 pL of potassium phosphate buffer (0.15 mol/L; 
pH 7.5), 25 pL of 6-MP (24 mmol/L), 20 pL of SAM (112.5 pmol/L), 10 pL of dithio- 
threitol (5.6 mmol/L), and 10 pL of allopurinol (450 pmol/L) for 1 hour at 37°C. 
The reaction was stopped by adding 50 pL of hydrochloride (1 tool/L), and then 
metronidazole was added as the internal standard. 6-MeMP was extracted into 
dichloromethane-2-propanol (80:20 v/v). After being centrifuged, the organic 
phase was evaporated with nitrogen until dry, and the residue was dissolved in 
120 pL of mobile phase. An injection volume of 50 pL was selected. 6-MeMP was 
assayed using a UV detector (~, = 290 nm) with a reverse-phase C18 column (Shim- 
pack, CLC-ODS, 6 mm × 150 mm, 5-pm internal diameter, Shimadzu, Kyoto, 
Japan). The mobile phase consisted of methanol, water, and triethylamine in a 
24.0:75.6:0.4 ratio (v/v), and the flow rate was maintained at 1.0 mL/min. A stan- 
dard curve ranging from 50 to 2000 ng/mL was selected, and linearity was con- 
firmed by linear regression (r-- 0.9996). The CVs were 4.29% for the interday and 
intraday assays, and the recoveries were between 94.9% and 103.2% in control 
samples. In a blood sample from one of the authors (B.Z.), which was used as a 
control sample, the intraday and interday CVs of TPMT activity were 3.29% and 
3.25%, respectively, throughout the course of the study. 
TPMT activity was expressed as nanomoles of 6-MP formed per hour per mil- 
liliter of packed RBCs (nmol/h • mL-1). 
6-Thioguanine Nucleotide Concentration Assay 
We developed an HPLC method to determine the 6-TGN Css in RBCs with slight 
modifications based on those by Dervieux and Boulieu. 19 6-MP was introduced 
into this method as the internal standard. The retention time of 6-MP was 
determined to be similar to that of azathioprine; no interference peaks were 
found. The stability of 6-MP was verified using HPLC. 
6-TGN Css was determined using a UV detector (~. = 345 nm) with the reverse- 
phase C18 column. The mobile phase consisted of methanol, water, and trieth- 
ylamine in a 10.0:89.8:0.2 ratio (v/v). An injection volume of 50 pL was selected, and 
the flow rate was maintained at 1.0 mL/min. Protein was removed from 200 pL of 
RBCs using 70% perchloric acid with dithiothreitol. The nucleotides were 
hydrolyzed to their base 6-thioguanine (6-TG) by heating the supernatant for I hour 
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at 100°C. A standard curve ranging from 5 to 750 ng/mL was selected, and lin- 
earity was confirmed by linear regression (r = 0.9997). The intraday and inter- 
day CVs obtained in checked samples ranged from 2.27% to 6.27%, and the 
recoveries in the samples ranged from 96.9% to 101.7%. 
6-TGN C~s was expressed as nanograms of 6-TG per 8 × 10 8 RBCs (ng/8 × 10 8 
~Cs) .  
Statistical Analysis 
The correlation between variables was determined with the Spearman on- 
parametric rank correlation analysis using SPSS version 10.0 (SPSS Inc., 
Chicago, Illinois). P < 0.01 and ~ -- 0.01 were considered statistically significant. 
No power analysis was done to determine sample size a priori. 
RESULTS 
Study Population 
Nineteen patients (14 women, 5 men; mean [SD] age, 41 [9.6] years [range, 
22-59 years]; mean [SD'] weight, 62 [12] kg) were enrolled in this study (Table I). 
Seven of the 19 patients were enrolled in the subanalysis. 
Thiopurine Methyltransferase Activity and 6-Thioguanine Nucleotide 
Concentrations in Red Blood Cells 
TPMT activity in the 19 patients ranged from 3.50 to 17.87 nmol/h • mL -1 
RBCs. Mean (SD) TPMT activity was 12.95 (3.07) nmol/h • mL -1 RBCs, and the 
interindividual CV was 23.68% (Table II). 
6-TGN Cs~ in the RBCs of the 19 patients ranged from 7.56 to 187.73 ng/8 × 
l0 s RBCs. Mean (SD) 6-TGN Css was 42.95 (41.98) ng/8 × 108 RBCs, and the 
interindividual CV was 97.74% (Table II). A 24.8-fold interindividual variation 
in 6-TGN Css, which was larger than that in TPMT activity (5.11-fold), was 
observed. 
Correlation Analysis 
No significant correlation was found between the dose of azathioprine and 
6-TGN Css in RBCs. A significant negative correlation was found between TPMT 
activity and 6-TGN Css in RBCs (r -- -0.712; P = 0.001). However, when the outlier 
data (6-TGN Css, 187.73 ng/8 × 108 RBCs; TPMT activity, 3.5 nmol/h • mL -1 RBCs) 
were removed, no significant correlation was observed. A scatterplot of TPMT 
activity and 6-TGN Css values is shown in Figure 2. 
Pharmacokinetic Properties of 6-Thioguanine Nucleotides 
In the subanalysis, little intraindividual variation was found in 6-TGN Css 
within 8 hours after azathioprine administration, and the CV was between 4.23% 
and 7.37%. The concentration-time curves of 6-TGNs in the RBCs in these 
7 patients after PO azathioprine 100 mg are shown in Figure 3. 
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Table I. Baseline demographic and clinical characteristics of 19 Han Chinese patients 
with immunosuppression. 
Patient Age, Weight, Azathioprine 
No. Sex y kg Dose, mg/d Diagnosis 
1 F 32 41 50 SLE 
2 F 30 61 25 SLE 
3 F 22 64 100 LN 
4 F 28 55 50 CTD 
5 F 40 85 50 SLE 
6 F 47 62 100 CTD 
7 F 54 55 50 SS 
8 F 37 45 100 LN 
9 F 50 61 100 AIH 
10 F 42 75 50 SS 
11 F 43 57 100 SLE 
12 F 30 62 50 SLE 
13 F 35 42 100 KT 
14 M 43 70 50 KT 
15 M 46 65 100 KT 
16 M 50 78 100 KT 
17 M 46 75 100 KT 
18 F 38 51 100 KT 
19 M 59 75 100 KT 
All patients 
Mean (SD) 41 (9.6) 62 (12.0) 78 (28.0) - 
CV, % 23.41 19.35 35.90 - 
F = female; SLE = systemic lupus erythematosus; LN = lupus nephritis; CTD = connective tissue disease; 
SS = Sj6gren's yndrome; AIH = autoimmune hepatitis; KT = kidney transplantation; M = male. 
The WBC count in 1 patient who was not included in the subanalysis 
decreased from 4.5 × 109 cells/L to 3.8 × 109 cells/L. Following the study's pro- 
tocol, azathioprine treatment was then discontinued and blood samples were 
collected weekly after discontinuation. Four weeks after discontinuation f aza- 
thioprine, the patient's WBC count had returned to normal (5.8 × 109 cells/L). 
The tl/2 of 6-TGN in the RBCs of this patient was 5.85 days (Figure 4). 
To lerab i l i ty  
No deaths or serious adverse vents occurred. The only abnormal labora- 
tory test result was the low WBC count (3.8 × 109 cells/L) in 1 patient. No other 
adverse vents were reported in the remaining 18 patients. 
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Table II. Thiopurine methyltransferase (TPMT) activity and 6-thioguanine nucleotide 
(6-TGN) concentration in red blood cells (RBCs) from 19 Han Chinese pa- 
tients with immunosuppression treated with azathioprine 25 to 100 mg for 
1 year. 
Patient TPMT Activity, 6-TGN Concentration, 
No. nmol/h • mL -1 RBCs ng/8 x 108 RBCs 
1 13.65 16.14 
2 14.51 7.56 
3 14.14 31.62 
4 12.13 13.97 
5 8.80 31.24 
6 16.36 45.17 
7 12.39 26.33 
8 1 7.87 9.84 
9 13.72 65.16 
10 3.50 187.73 
11 14.39 40.88 
12 13.66 20.78 
13 14.12 84.79 
14 14.16 43.69 
15 10.01 89.16 
16 12.27 31.65 
1 7 1 3.76 32.33 
18 14.96 14.47 
19 11.62 23.55 
All patients 
Mean (SD) 12.95 (3.07) 42.95 (41.98) 
CV, % 23.68 97.74 
DISCUSSION 
TPMT, which is an important enzyme in the metabolism of purine drugs (eg, 
azathioprine, 6-MP, and 6-TG), is characterized by genetic polymorphisms and 
ethnic variations. In this study, a significant negative correlation between TPMT 
activity and 6-TGN Css in RBCs (r = -0.712; P -- 0.001) was found in 19 patients, 
which was consistent with the results of previous tudies. 11-13 
One patient in this study had the highest 6-TGN concentration and the low- 
est TPMT activity in the study. When the data for that patient were removed, 
the correlation between TPMT activity and 6-TGN Css in RBCs was no longer 
significant. In our opinion, this was a rare case and further studies (eg, geno- 
type analysis and pharmacokinetic studies) should be done. This information 
was only determined after the physician had already recommended discontin- 
uation of azathioprine based on the opinion that the patient would not bene- 
277 
CURRENT THERAPEUTIC RESEARCH 
200 
.o ~, 150 
c " 100 
o x 
Z 
Oc 
I- '.-" 50 
I I I I 
0 5 10 15 20 
TPMT Activity 
(nmol/h • mL -1 RBCs) 
Figure 2. Thiopurine methyltransferase (TPMT) activity and steady-state concentra- 
tion of 6-thioguanine nucleotides (6-TGNs) in red blood cells (RBCs) in Han 
Chinese patients with immunosuppression treated with azathioprine 25 to 
100 mg for 1 year (N = 19) (r = -0.712; P = 0.001). 
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Figure 3. Concentration-time curve of 6-thioguanine nucleotides (6-TGNs) in red blood 
cells (RBCs) in Han Chinese patients with immunosuppression treated with 
azathioprine 100 mg for 1 year (n = 7). 
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Figure 4. Concentrat ion-t ime curve of 6-thioguanine nucleotides (6-TGNs) in red 
blood cells in the 1 Han Chinese patient whose azathioprine treatment 
was discontinued due to a low (3.8 × 10 9 cells/L) white blood cell count. 
log C = logarithm of 6-TGN concentration. 
fit from the treatment. The response to the high 6-TGN Css might have been 
associated with increased toxicity if this patient had continued treatment with 
azathioprine. 
As for the pharmacokinetic properties of 6-TGNs in RBCs, little intraindivid- 
ual variation in 6-TGN Css (~7.37%) was found within 8 hours of azathioprine 
administration, suggesting that if it becomes necessary to monitor 6-TGN con- 
centrations in clinical practice, then blood samples can be collected within 
8 hours of azathioprine ingestion. 
The tl/2 of 6-TGN in RBCs was 5.85 days in the patient in whom a low WBC 
count developed. Lennard et al 2° reported that the tl/2 of 6-TGN in RBCs was -3 
to 13 days in kidney transplant recipients. The long tl/2 of 6-TGNs in our patient 
was consistent with the slow onset of action of azathioprine and the duration 
of recovery from myelotoxicity found by Lennard et al. Our patient's WBC count 
decreased from 4.5 × 109 cells/L to 3.8 × 109 cells/L on day 15 after the initia- 
tion of azathioprine treatment; however, the 6-TGN concentration i that 
patient was only 9.84 ng/8 × 10 s RBCs. Myelotoxicity has been reported in a 
heart transplant recipient whose 6-TGN Css was 369.68 ng/8 × 108 RBCs 21 and 
in a patient with juvenile human leukocyte antigen B27-associated spondyl- 
arthritis whose 6-TGN Css was 400.28 ng/8 × 10 s RBCs. 22 Given the differences 
in the concentration of 6-TGN in RBCs found in those studies, it appears un- 
likely that the case of myelotoxicity in our study was associated with 6-TGNs. 
Our study had several limitations. First, the number of patients in this study 
was small (N = 19), and only 1 patient had low TPMT activity, which was not 
unexpected given the low frequency of a mutant allele in the Han Chinese pop- 
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ulation ~4.7%). 4 Second, the patients were clinically heterogeneous (12 had auto- 
immune diseases and 7 were kidney transplant recipients). Finally, genotype 
analysis was not performed in this study. Factors other than TPMT activity 
might have affected the 6-TGN Css, such as variation in XO or HGPRT activities 
and/or bioavailability of azathioprine. 
In clinical practice, azathioprine toxicity is monitored using routine blood 
tests. A WBC count of <4 x 109 cells/L indicates myelotoxicity, and recovery 
from myelotoxicity might be quite difficult, making the initial dose of azathio- 
prine important. Our study found a negative correlation between TPMT activity 
and 6-TGN Css in these Han Chinese patients treated with azathioprine. Because 
patients with low or absent RBC TPMT activity may be at increased risk for 
complications due to elevated 6-TGN Css, it may be useful to measure RBC 
TPMT activity before beginning azathioprine treatment. In patients with low or 
absent activity, the azathioprine dose might need to be reduced at the begin- 
ning of treatment to prevent serious adverse vents, and such patients hould 
be carefully monitored. In patients with high TPMT activity, the 6-TGN Css might 
be less than that considered therapeutic, which could necessitate increasing 
the dose of azathioprine to achieve a therapeutic outcome. 
CONCLUSION 
In this small study, a significant negative correlation was found between TPMT 
activity and 6-TGN Css in RBCs in these Han Chinese patients receiving a stable 
dose of azathioprine as part of a regular treatment regimen for immunosuppres- 
sion. However, the correlation was not significant when the outlier data were 
excluded. 
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